A Whirlwind of Change in Lung Cancer

Meir Rinde
Published: Tuesday, May 22, 2018
Corey Langer, MD
Corey Langer, MD
Less than 3 years after the first checkpoint blockade immunotherapies were introduced for non–small cell lung cancer (NSCLC), the treatment paradigm is poised for dramatic changes in frontline care for patients with metastatic disease.

.

Table. Key Findings in Frontline Lung Cancer Studies

Pembrolizumab Findings

In the KEYNOTE-189 trial, investigators found that pembrolizumab with pemetrexed (Alimta) and either cisplatin or carboplatin showed a much greater benefit than chemotherapy alone, reducing the risk of death by over 50% in patients with nonsquamous NSCLC without EGFR or ALK mutations.1,2 At a median follow-up of 10.5 months, the estimated 12-month overall survival (OS) rate was 69.2% (95% CI, 64.1%-73.8%) in the pembrolizumab arm compared with 49.4% (95% CI, 42.1%-56.2%) in the control group (HR, 0.49; 95% CI, 0.38-0.64; P <.001).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x